Ashling Wahner's profile photo

Ashling Wahner

Bordentown

Assistant Editor at OncLive

Featured in: Favicon onclive.com Favicon newsbreak.com Favicon ajmc.com Favicon cancernetwork.com Favicon curetoday.com Favicon diagnosticimaging.com Favicon targetedonc.com Favicon urologytimes.com Favicon friendsofcancerresearch.org Favicon oncnursingnews.com

Articles

  • Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL

    6 days ago | onclive.com | Ashling Wahner

    Pirtobrutinib (Jaypirca)—the first noncovalent BTK inhibitor approved for patients with chronic lymphocytic leukemia (CLL)—has reshaped third-line treatment strategies in this disease space and prompted new considerations regarding treatment sequencing and patient selection as the paradigm grows more complex, according to Nicole Lamanna, MD.

  • Limited Role for ICI Rechallenge in RCC Spurs Interest in More Tailored Later-Line Strategies

    1 week ago | onclive.com | Ashling Wahner

    Despite the lack of clinical benefit generated by immune checkpoint inhibitor (ICI) rechallenge for most patients with advanced renal cell carcinoma (RCC) who have progressed on prior immunotherapy, ongoing research is seeking to clarify the application of this strategy in select patient subgroups, according to Evan T. Hall, MD, MPhil, who added that increasingly tailored later-line RCC regimens are also of interest for this patient population.

  • SCG101 Shows Antiviral and Antitumor Activity in Advanced HBV-Related HCC

    1 week ago | onclive.com | Ashling Wahner

    Treatment with SCG101, an autologous hepatitis B virus (HBV)–specific T-cell therapy, led to sustained HBV-DNA and serum hepatitis B surface antigen (HBsAg) clearance in patients with advanced HBV-related hepatocellular carcinoma (HCC), according to findings from a phase 1 trial (NCT06617000) presented at the 2025 European Association for the Study of the Liver Congress.1 All 17 patients with heavily pretreated HBV-related HCC who received a single infusion of SCG101 in the trial showed rapid...

  • Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management

    1 week ago | onclive.com | Ashling Wahner

    Evolving insights and maturing data from bladder cancer clinical trials, such as the phase 3 CheckMate 274 trial (NCT02632409) evaluating adjuvant nivolumab (Opdivo) in patients with muscle-invasive bladder cancer (MIBC), are prompting further considerations for adjuvant treatment strategies that may better personalize care and enable bladder preservation, according to Petros Grivas, MD, PhD.

  • NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

    1 week ago | onclive.com | Ashling Wahner

    Practice-changing results with the addition of perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy have both refined the management of muscle-invasive bladder cancer (MIBC) and raised questions regarding the optimal comparator arms to use in future investigations of immunotherapy in this disease, according to Petros Grivas, MD, PhD.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →